Plus, news about Tarsus Pharmaceuticals and Biohaven:
Brise Pharmaceuticals raises $20M: The funding comes from Shunxi Fund, Sherpa Healthcare Partners and Qiming Ventures, among other investors. The Shanghai-based company is developing therapies for acute and chronic pain. It began an early-stage clinical study of a chronic low back pain treatment in the US last year. — Lei Lei Wu
Taro shareholder rebels against Sun Pharma’s buyout offer: Krensavage Asset Management — Taro Pharmaceutical Industries’ largest minority shareholder — said the generics maker’s proposed buyout is based “on an investment bank’s flawed analysis.” Back in January, Sun announced it would convert its majority ownership of Taro into a full takeover, paying $43 a share in cash for shares that it doesn’t already own. According to Krensavage, the deal undervalues Taro by roughly 44%. — Katherine Lewin
Tarsus secures new capital: The company can draw $75 million out of $200 million provided by Pharmakon Advisors. — Jaimy Lee
Biohaven raised $264.5 million in a public offering, surpassing the $230 million it had intended to bring in. — Jaimy Lee